Medtronic Reveals Plans For Next-Generation ‘Drug-Filled’ Stent
This article was originally published in The Gray Sheet
Executive Summary
The firm characterizes the early-stage technology as its answer to Abbott’s bioabsorbable vascular scaffold and Boston Scientific’s bioabsorbable polymer coronary stents.
You may also be interested in...
Research In Brief
Covidien's Pipeline aneurysm device shows 8.5% major complication rate in early post-market results. Surprise at long-term results for endovascular repair of abdominal aortic aneurysms. More clinical trial news.
New Products In Brief
Recent debuts include NuVasive’s PCM cervical disk system, Boston Scientific’s bioabsorbable Synergy drug-eluting stent in Europe and Medtronic’s MRI-safe Advisa pacemaker in Japan.
New Products In Brief
Recent launches and approvals include overseas debuts of Abbott’s Absorb bioabsorbable vascular scaffold and Medtronic’s next-generation CoreValve Evolut transcatheter aortic heart valve.